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Abstract 
Background: Many studies report associations between human genetic factors and immunity to malaria but few 
have been reliably replicated. These studies are usually country‑specific, use small sample sizes and are not directly 
comparable due to differences in methodologies. This study brings together samples and data collected from mul‑
tiple sites across Africa and Asia to use standardized methods to look for consistent genetic effects on anti‑malarial 
antibody levels.
Methods: Sera, DNA samples and clinical data were collected from 13,299 individuals from ten sites in Senegal, Mali, 
Burkina Faso, Sudan, Kenya, Tanzania, and Sri Lanka using standardized methods. DNA was extracted and typed for 
202 Single Nucleotide Polymorphisms with known associations to malaria or antibody production, and antibody 
levels to four clinical grade malarial antigens [AMA1, MSP1, MSP2, and (NANP)4] plus total IgE were measured by ELISA 
techniques. Regression models were used to investigate the associations of clinical and genetic factors with antibody 
levels.
Results: Malaria infection increased levels of antibodies to malaria antigens and, as expected, stable predictors of 
anti‑malarial antibody levels included age, seasonality, location, and ethnicity. Correlations between antibodies to 
blood‑stage antigens AMA1, MSP1 and MSP2 were higher between themselves than with antibodies to the (NANP)4 
epitope of the pre‑erythrocytic circumsporozoite protein, while there was little or no correlation with total IgE levels. 
Individuals with sickle cell trait had significantly lower antibody levels to all blood‑stage antigens, and recessive 
homozygotes for CD36 (rs321198) had significantly lower anti‑malarial antibody levels to MSP2.
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Background
Despite many years of research and intervention, malaria 
remains a major global health concern. Approximately 
half of the world’s population is at risk, and in 2013 there 
were 207 million estimated cases of malaria and 627,000 
deaths [1]. Malaria has been described as the strongest 
evolutionary force in the recent history of the human 
genome (reviewed in [2]) and exerts a selective pressure 
that has resulted in a number of genetic adaptations. 
These adaptations predominantly cause erythrocyte 
defects, which affect the binding, invasion and growth of 
malaria parasites; however, there is also evidence to sug-
gest that genetic factors influencing humoral immune 
responses may account for differences in susceptibility to 
malaria [3].
A number of studies have investigated the heritability of 
antibody responses against specific malaria antigens. For 
example, Sjoberg et al. [4] found that antibody response 
to ring-infected erythrocyte surface antigen (RESA) is 
more concordant between monozygotic twins than either 
dizygotic twins or age- and sex-matched siblings in Libe-
ria and Madagascar. In Burkina Faso sibling correlations 
were observed for IgG and IgG subclass responses to 
RESA, merozoite surface protein 1 (MSP1), MSP2 and 
Plasmodium falciparum extract, whilst parent-offspring 
correlations were observed for IgG responses to MSP2 
[5]. A study in Papua New Guinea found substantial her-
itability for IgG subclass responses to RESA and MSP2 
and showed that this genetic variation was not domi-
nated by a single major gene, suggesting multifactorial 
inheritance for IgG responses to malaria antigens [6–8].
Genetic variability in host immune response genes 
may account for differences in susceptibility to malaria 
between sympatric ethnic groups. For example, Luoni 
et al. [9] found in Mali that the IL4-524 T allele, associ-
ated with immunoglobulin (Ig) switching from IgG/IgM 
to IgE, is significantly more common in Fulani than in 
Mossi or Rimaibe and is associated with significantly 
higher IgG levels to CSP and Pf332 malaria antigens 
[9]. Also in Mali, differences in IgG sub-class levels have 
been seen between the Fulani and Dogon [10, 11] for the 
immunoglobulin receptor FcRIIa 131 (R/H) and the IL4-
590 polymorphisms.
Many such immune-epidemiological studies are coun-
try-specific and have involved relatively small sample 
sizes providing different lines of evidence that have not 
always been independently replicated. To address this 
problem a large multi-centre study was undertaken to 
explore the associations between host genetic factors 
and their immune responses to malaria antigens at ten 
locations in Senegal, Mali (2 sites), Burkina Faso, Sudan, 
Kenya, Tanzania (3 sites), and Sri Lanka. Each site pro-
vided serum, DNA and clinical data. Standardized meth-
ods were used to genotype 202 polymorphisms (with 
previous malaria or antibody associations) and four IgG 
antibody levels to the malaria antigens AMA1, MSP1, 
MSP2, (NANP)4, plus total IgE levels. Despite the chal-
lenges of combining data from these heterogeneous study 
designs and backgrounds, a resource of 13,299 individu-
als was created to look for consistent genetic effects on 
anti-malarial antibodies.
Methods
Ethical approval
Ethical approval was granted separately for each study 
by their respective Ethics Review Committee (see Addi-
tional file 1) Ethical approval was also granted to Malaria-
GEN by the Oxford Tropical Research Ethics Committee. 
Informed consent was obtained from all participants 
before data or samples were collected.
Study designs
Studies were conducted at ten sites in seven countries 
across West Africa, East Africa and Asia; details of study 
design at individual sites and local epidemiological con-
ditions including malaria endemicity are described else-
where (see [12–18]). Each site provided a DNA sample, 
serum sample and clinical data for participants collected 
at a single time point; at several sites these were pro-
vided as part of an ongoing study, while at others these 
were provided from a new study or as an extension to an 
earlier study. The clinical parameters measured at each 
site were influenced by study design, which varied con-
siderably (Additional files 1 and 2). Sites either collected 
cross-sectional data only, longitudinal data only or a 
combination of both.
Clinical data collection
At the outset investigators selected a core set of clini-
cal parameters to be collected by all sites, taking into 
Conclusion: Although the most significant finding with a consistent effect across sites was for sickle cell trait, its 
effect is likely to be via reducing a microscopically positive parasitaemia rather than directly on antibody levels. How‑
ever, this study does demonstrate a framework for the feasibility of combining data from sites with heterogeneous 
malaria transmission levels across Africa and Asia with which to explore genetic effects on anti‑malarial immunity.
Keywords: Malaria, Antibody, Sickle cell trait, HbAS, CD36, Genotype
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account variations in study design and implementa-
tion, and agreed on methods for recording these clini-
cal measurements to encourage uniformity across the 
data. These clinical parameters were chosen based on 
their previous association with malaria infection or anti-
malarial immune responses (Additional file 2). Data were 
submitted to the MalariaGEN resource centre where 
it was uploaded into a secure central database (no per-
sonal information was stored by MalariaGEN or used in 
any analyses). Once uploaded the data were converted to 
standardized units, formatted and combined with clini-
cal data from other sites to create a full normalized and 
consistent dataset.
Sample collection
Blood samples were collected from participants by veni-
puncture into plain tubes for serum separation or EDTA-
coated tubes for DNA extraction. The volume of blood 
collected varied from <1  ml to 10  ml depending on the 
clinical settings and ethical permissions of the indi-
vidual sites. Clinical data were also collected from each 
participant at the time of sampling and each participant 
was assigned a unique identification code to allow their 
samples and clinical records to be matched for statistical 
analysis.
DNA extraction and genotyping
DNA extraction was performed at each site using 
the local method of choice; either Nucleon™ BACC 
Genomic Extraction Kits (GE Lifesciences, [19]) or Qia-
gen DNeasy Blood Kits (Qiagen, Crawley, UK, [20]), and 
DNA samples were then shipped frozen to the Malaria-
GEN resource centre in Oxford. Sequenom iPLEX Gold 
(Agena Bioscience, CA, USA) was chosen for genotyp-
ing because of its high-throughput capacity, flexibility for 
assay design and ability to genotype up to 40 SNPs (Sin-
gle Nucloetide Polymorphisms) in one reaction. Multi-
plexes were designed using MassARRAY® Assay Design 
software (Agena Bioscience) and assays with poor perfor-
mance or concordance were removed from the multiplex 
during testing. A total of 202 SNP-assays were designed. 
These included a set of 65 that have been analysed in a 
severe malaria case–control study across 11 countries 
[21] plus a further 137 autosomal SNPs selected in genes 
associated with or described as playing a role in malaria 
and antibody production (Additional file  3 contains 
details of the gene regions and SNPs assay multiplexes; 
Additional file 4 contains further details of the genotyp-
ing methodology).
Measurement of immune responses
All study sites supplied serum or plasma samples to a 
central repository established at the National Institute 
for Biological Standards and Control (NIBSC). Samples 
were divided into two aliquots and stored at −80  °C in 
individually barcoded tubes (Matrix systems, Thermo 
Fisher Scientifics, Horsham, UK) and racks. Before stor-
age, a 5-µl aliquot was removed and diluted to 50  µl 
in PBS-0.2  % (w/v) sodium azide in a storage plate in 
order to characterize each sample. This characterization 
took the form of assaying specific antibody levels to the 
recombinant P. falciparum erythrocytic stage parasite 
proteins apical membrane antigen 1 (AMA1), merozoite 
surface protein 2 (MSP2) and merozoite surface protein 
1, 19 kDa fragment (MSP119). In addition, antibodies to a 
synthetic peptide (NANP)4 representing the major B cell 
epitope repeat of the circumsporozoite protein (CSP) of 
P. falciparum, and the amount of total IgE, were meas-
ured. Assays were carried out using a single uniform 
combined protocol for all samples.
Antigens
Recombinant AMA1 (3D7 sequence) [22], MSP2 (3D7 
sequence) [23] and MSP119 (Wellcome sequence) [24] 
were all of vaccine quality. AMA1 was kind gift of Alan 
Saul (Malaria Vaccine Development Unit, NIAID, USA), 
MSP2 of Robin Anders (La Trobe University, Melbourne, 
Australia) and MSP119 of Shirley Longacre (Pasteur Insti-
tute, Paris, France). The 16 residue synthetic peptide 
(Asn-Ala-Asn-Pro)4 (NANP)4 was a kind gift of Eric Ton-
gren (CDC, Atlanta, USA).
Serum references
A reference plasma pool obtained from 20 malaria-
exposed adults in the Gambia (Brefet4 pool) [25] was 
used as a P. falciparum standard on each plate coated 
with malaria antigen and the IgE reference serum, 75/502 
(NIBSC), was used for IgE determinations. The negative 
control serum was a pool of 40 European individuals who 
had never been exposed to malaria.
ELISA
ELISA was carried out as previously described [25] and as 
detailed in Additional file 4 Briefly, ELISA plates (Immu-
lon 4-HBX, Fisher Scientific UK Ltd, Loughborough, UK) 
were coated with antigen (50  µl in 0.05  M sodium car-
bonate pH 9.6) at a concentration of 0.5 µg/ml (AMA1, 
MSP2 and IgE) or 1  µg/ml (MSP119 and (NANP)4) or 
anti-human IgE MAb (M107 from Mabtech AB, Nacka 
Strand, Sweden) (50 µl of 1 µg/ml), incubated overnight 
at 4  °C, washed three-fold with PBS-0.05  % Tween 20 
(PBS/T) (Sigma, Gillingham, Dorset, UK), blocked with 
200  µl of blocking solution (2  % skimmed milk powder 
in PBS/T) for 3  h at ambient temperature and washed 
three times with PBS/T. Samples of each characteriza-
tion sample (see above) were diluted in blocking solution 
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and aliquots added in duplicate to plates as follows : 
50  µl of 1:200 final dilution for (NANP)4-coated plates; 
50 µl of 1:1,000 final dilution for MSP119, MSP2 and IgE 
and 100  µl of 1:2,000 for AMA1 plates. After overnight 
incubation at 4  °C, plates were washed six times with 
PBS/T, 50  µl of horseradish peroxidise-conjugated rab-
bit anti-human IgG (DAKO) (1:5,000 in PBS/T) added 
to each well and plates incubated for 3  h at room tem-
perature. Following six-fold washing in PBS/T, 100 µl of 
Sigma-Fast o-phenylenediamine dihydrochloride (OPD) 
reagent solution (Sigma) was added to each well. Plates 
were developed at room temperature for 10–15  min 
(20–30 min for (NANP)4 ELISA), the reaction stopped by 
addition of 25  µl 2  M H2SO4 and plates read in a plate 
reader (Molecular Devices, Wokingham, Berkshire, UK) 
at 492 nm. A standard curve was fitted to the reference 
serum data obtained for each antigen as previously out-
lined [25] with the reference serum assigned an arbitrary 
concentration of 1,000 U/ml for all antigens. Plate values 
were normalized using the standard curves, and sample 
antibody concentrations (in U/ml) were calculated (see 
Additional file 4). For the Tanzania (Moshi) ELISAs, only 
three values were obtained, those for AMA1, MSP119 and 
MSP2, using independently expressed preparations of the 
same antigens (see Additional file 4).
Determination of malaria status
Thick and/or thin blood films were used to determine 
malaria status and all data were transformed to a stand-
ard parasites/µl.
Data cleaning
To create the final dataset for analysis the clinical, genetic 
and antibody data were merged based on the unique ID 
code assigned to each participant at the time of sam-
pling. Entries that did not contain all three data compo-
nents after merging were removed. Duplicated ID codes 
were resolved if the correct entry could be identified, 
otherwise both entries were removed. This gave a data-
set with 15,216 individuals. Records where gender miss-
matched between clinical and genetic gender or DNA 
samples with <90 % pass rate across 65 core SNP assays 
[21] were also removed (540 miss-matched gender, 1,237 
<90 % pass-rate and 140 both miss-matched gender and 
pass-rate), leaving 13,299 individuals in the merged data-
set eligible for analysis. This dataset was then used to 
quality control the remaining 137 SNP-assays, removing 
assays with pass rates <80 % across all samples (n =  3). 
Assays for SNPs monomorphic across all sites (n =  18) 
or Amelogenin [gender determining (n =  3)] were also 
removed from further analysis leaving a total of 178 SNPs 
for analysis (65 core and 113 extra).
Antibody titres were log base 10 transformed to obtain 
approximate normal distributions for parametric analy-
ses. Once logged all anti-malarial antibodies showed 
some evidence of a bimodal distribution, while IgE lev-
els showed a negatively skewed distribution (Additional 
file 5). In the MSP-1 data (Additional file 5) a number of 
individuals were identified (log10 titre of 4.85, n = 216) 
that were not measured correctly due to technical diffi-
culties. These were removed and excluded from further 
analyses. Plots of the residuals from the regression anal-
yses (see below) were made (Additional file 6) in order to 
check that the antibody data were normally distributed.
Statistical analysis
All analyses were carried out using the statistical package 
R [26, 27]. Standard linear regression models were used 
to investigate associations between non-genetic factors 
and antibody levels at all sites combined. Covariates were 
included in the main analyses if they were collected by all 
sites and were associated with antibody levels; parasite 
density and bed-net use were not covariates in this model 
as they were not measured at all sites; separate regres-
sion models were run for the subset of sites that provided 
these data. Details of the linear regression models used 
are given in Additional file 7.
Tests of association between each SNP and antibody 
levels with adjustment for age, gender, malaria status, 
ethnicity, village, and sample month were run using 
standard linear regression models at each site under 
a variety of modes of inheritance: additive, dominant, 
recessive, and heterozygote (Additional file  7). Results 
at each site were meta-analysed to obtain the effect of 
genotype on antibody level. Meta-analysis provided a 
beta coefficient and p-value for each SNP-antibody asso-
ciation using each model. A standard Bonferroni correc-
tion based on analysis of association between 178 SNPs 
and antibody levels to 5 antigens would give threshold 
for significance of 6  ×  10−5. A more accurate signifi-
cance threshold would need to take into account the 
level of linkage disequilibrium between SNPs, but this 
is difficult to estimate across multiple different popu-
lations. The Bonferroni significance threshold should, 
therefore, be regarded as an approximation and probably 
over-conservative.
Logistic regression was used to investigate the effect 
of SNPs with significant SNP-antibody associations on 
microscopic malaria infection, adjusted for relevant clini-
cal parameters (Additional file  7). Data from Senegal, 
Mali (Pongonon), Sudan and Sri Lanka were not included 
in this analysis as their study populations were either 
entirely microscopically negative or entirely microscopi-
cally positive for malaria at the time of sampling.
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Linear regression was used to investigate the effect 
of SNPs with significant SNP-antibody associations on 
parasite density, adjusted for relevant clinical parameters 
(Additional file 7). Data from Senegal, Kenya, Sudan, and 
Sri Lanka were not included in this analysis as parasite 
density was not recorded at these sites.
In all regression models, age was included as a grouped 
rather than continuous variable to allow for a non-linear 
relationship with antibody levels. Sample month was 
included as a covariate in regression models as a proxy 
for rainy season, the timing of which varied between 
sites.
Results
Epidemiological factors
A number of study designs were used across sites; Mali 
(Manteourou), Burkina Faso and Tanzania studies col-
lected data during their malaria transmission season, 
Mali (Pongonon) included only individuals positive for 
malaria, Senegal and Sudan based data collection on 
active case detection, Kenya collected data as part of a 
birth cohort study at aged 7 years-old, and Sri Lanka fol-
lowed up individuals that had been malaria positive in 
1992/93. Further details can be found in Table  1, Addi-
tional file 1 and the MalariaGEN Website [18]. After data 
curation and quality control (see “Methods”), 13,299 
individuals were included for analysis (Table  1) for five 
antibodies and 178 SNPs. At all sites the ratio of males 
to females was approximately 1:1. The number of ethnic 
groups within a site varied, and individuals belonging to 
the Fulani ethnic group (referred to here as Peulh) were 
collected in Senegal, Manteourou in Mali and Burkina 
Faso. Altitude ranged from sea level (0 m) in the coastal 
town of Kilifi in Kenya to 1,845  m in the mountain-
ous areas of Moshi in Tanzania, and reported bed net 
usage ranged from 16.5  % in Burkina Faso to 95.7  % in 
Sri Lanka. In Senegal, Sudan and Mali (Pongonon) the 
malaria prevalence given in Table 1 was affected by data 
Fig. 1 Proportion of individuals microscopically Plasmodium falciparum positive. Data shown are for the six sites for which surveys sampled across 
different age groups. Studies not included here include: Mali (Pongonon) where only malaria positive were included, Kenya (where only one age 
group was sampled) and Sudan and Sri Lanka were all negative at the time of survey.
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availability or study design and thereby did not necessar-
ily reflect malaria prevalence in the general population at 
the time of sampling; at remaining sites the prevalence 
of microscopically detectable infection ranged from 0 % 
in Sri Lanka to 44.3  % in Burkina Faso. The prevalence 
of microscopically positive malaria infection is shown 
in Fig. 1 for the six sites having age-distributed commu-
nity data. Overall there was a general increase in preva-
lence from the <1  year-old age group to a peak in the 
5–15 years-old age group (OR = 3.49, P < 0.001; Table 2) 
with a decrease thereafter; the lowest prevalence was 
seen in those aged >30 years-old (OR = 0.63, P = 0.01). 
Compared to the <1  year-old group, parasite density 
increased in the 1–2 years-olds (beta = 0.26, P = 0.041) 
was similar in the 2–5  years-old group and was signifi-
cantly lower in the older age groups with the lowest den-
sity seen in >30  years-olds (beta  =  −0.62, P  =  <0.001; 
Additional file 8). No significant difference were found in 
the odds of having a microscopically positive blood smear 
between males and females (OR males vs female = 1.09, 
P = 0.109), although males had a marginally higher para-
site density than females (beta males vs females = 0.09, 
P = 0.005, Additional file 8).
Correlations between antibody levels
The greatest correlations were seen between antibodies 
to merozoite antigens (r2 range = 0.21–0.35), followed by 
correlations between these antibodies and anti-(NANP)4 
(r2 range  =  0.11–0.24), with total IgE showing little or 
no correlation with any of the anti-malarial antibod-
ies (r2 range = 0–0.01, Fig. 2 ‘Combined’ panel). Similar 
trends were observed at individual sites (Fig. 2), although 
some variation between sites was visible. This pattern of 
correlations remained after accounting for other clini-
cal variables as shown by the residuals from the regres-
sion analyses (Additional file  9). It is possible that the 
strengths of correlation between antibodies might 
depend on the level of infection, and thus depend on 
study site and the age of the individuals. Therefore, a lin-
ear regression model was applied using both age-groups 
and sites as categorical variables and no significant asso-
ciations were observed with study-site or for age-group 
(Additional files 10, 11).
Factors influencing antibody levels
Individuals living in malaria-endemic areas are known 
to acquire immunity with age, this can be observed in 
Table 2 Results of logistic regression analysis investigating the effect of age, gender and HbS genotype on malaria status 
as determined by microscopya using combined data.
Data from Senegal, Mali (Pongonon), Sudan and Sri Lanka are not included as participants are either entirely microscopically malaria-positive or malaria-negative.
Reference category is “negative” (n = 7261).
Results significant at 0.05 level are highlighted in italics.
ND: Results not shown as unable to obtain estimates for HbSS without any infected individuals.
NB: CI confidence interval, OR odds ratio.
a Also adjusted for altitude, village (>20), ethnicity (>20), sample month (>20) and study; results not shown.
Factor Adjusted OR (95 % CI) p-value Malaria status by microscopy
Individuals positive  
(total = 1,966)
Individuals negative  
(total = 7,261)
N (%) N (%)
Age (years)
 <1 1 37  (10.9) 303 (89.1)
 1–2 1.33 (0.87–2.05) 0.191 47  (17.2) 225 (82.7)
 2–5 2.65 (1.88–3.72) <0.001 311  (26.7) 854 (73.3)
 5–15 3.49 (2.53–4.86) <0.001 1,141  (25.6) 3,314 (74.4)
 15–30 1.21 (0.87–1.70) 0.263 281  (17.1) 1,365 (82.9)
 >30 0.63 (0.44–0.90) 0.010 147  (11.1) 1,177 (88.9)
Gender
 Female 1 1,044  (20.1) 4,142 (79.9)
 Male 1.09 (0.98–1.21) 0.109 922  (22.8) 3,119 (77.2)
HbS
 11 1 1,824  (21.4) 6,718 (78.6)
 12 0.75 (0.61–0.92) 0.005 136  (21.1) 508 (78.9)
 22 ND ND 0 (0) 8 (100)
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Fig. 3 as the increase in antibody titres to AMA1, MSP1, 
MSP2, and (NANP)4 across the different age groups. The 
trend for increasing anti-malarial antibody levels with 
age was confirmed using regression analysis on combined 
data across all sites, adjusting for gender, malaria infec-
tion, altitude, month, village, and ethnicity (Table 3). All 
anti-malarial antibodies showed significant increases 
with each age group compared to the <1 year-old group. 
However, no overall significant change was observed in 
IgE levels with age, apart from the 15–30 years-old group 
(beta = 0.22, P = 0.034). Gender was a significant factor 
for all antibodies (although anti-AMA1 was marginal, 
Table 3). 
Across all sites, antibody levels to AMA1, MSP1 and 
MSP2 were significantly increased in individuals with 
microscopically detectable infection (Table  3); whilst at 
the six sites that quantified parasitaemia, increasing para-
site density was significantly associated with decreased 
antibody levels to AMA1, MSP1 and MSP2 (Additional 
file  12). There was no significant association of micro-
scopic positivity or parasite density on anti-(NANP)4 
levels. Total IgE levels were slightly raised in infected 
individuals (beta = 0.06, P = 0.021; Table 3) but did not 
differ significantly with increasing parasite density (Addi-
tional file  12). Similar trends were observed when this 
analysis was run for each site separately, although signifi-
cance was influenced by sample size (Additional file 13). 
At five sites that recorded bed-net use at the time of sam-
pling, no observed significant effect was seen for anti-
body levels (Additional file 14).
Allele frequency of SNPs
Allele frequencies in Sri Lanka were generally different to 
those observed at African sites (Additional file 15). Most 
notably, the DARC gene SNP-derived allele (rs2814778) 
was not observed in Sri Lanka but was at a frequency 
Fig. 2 Heatmap matrix plot of correlations between logged antibody titres at each site. Pairwise correlations between logged anti‑AMA1, anti‑
MSP1, anti‑MSP2, anti‑NANP, and total IgE calculated as R‑squared. Strongest correlations shown in red and weakest correlations shown in yellow. 
Correlations of antibodies with themselves shown here in grey.
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>0.99 in the African populations. Differences in allele 
frequencies between East and West African populations 
were also observed: the CD36 gene SNP (rs3211938) 
had a mean derived allele frequency of 28.9  % (range 
0.7–61.9 %) in West Africa compared to 7.2 % (range 2.7–
9.8 %) in East Africa; the HBB gene SNPs (rs334; HbS and 
rs33930165; HbC) had mean derived allele frequencies 
of 3.5 % (range 1.5–4.6 %) and 5.5 % (range 0.7–10.2 %), 
respectively, in West Africa compared to 5.9  % (range 
1.6–7.7 %) and 0.006 % (range 0.0–0.003 %) respectively 
in East Africa. SNPs that were polymorphic in East 
Africa but not in West Africa included three RAD50 gene 
SNPs (rs28903086, rs28903088, rs28903092), one IL4 
SNP (rs4986964), one IFNGR1 gene SNP (rs11575936) 
and two STAT6 gene SNPs (rs3024978, rs3024952). An 
FCER2 gene SNP (rs35825847) was the only SNP poly-
morphic in West Africa but not in East Africa.
SNP-antibody association analyses
Figure  4 shows the nominal P values from analysis of 
the SNP-antibody associations across all sites. The 
only candidate SNP that met the Bonferroni-corrected 
Fig. 3 Mean logged antibody titre for the five measured antibodies, for each age‑group for each site. Each colour represents a different antibody 
while the shape of the point represents the antibody type: (triangle) for anti‑merozoite, (square) for anti‑sporozoite, and (circle) for total IgE.
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significance threshold (P = 6 × 10−5, see Methods) was 
rs334 in HBB, encoding sickle haemoglobin. Compared 
to HbAA, HbAS individuals had lower concentrations of 
antibodies to merozoite antigens AMA1 (beta = −0.17, 
P = 2.9 × 10−7), MSP1 (beta = −0.15, P = 1.3 × 10−6) 
and MSP2 (beta = -0.14, P = 6.5 × 10−7). No association 
of HbAS was seen for anti-(NANP)4 antibodies.
A candidate SNP in CD36 came close to the Bon-
ferroni-corrected threshold, which is probably over-
conservative. Compared to ancestral homozygotes and 
heterozygotes combined, recessive homozygotes at 
rs3211938 (CD36) had significantly lower concentrations 
of antibodies to MSP2 (beta = −0.23, P = 7.7 × 10−5).
Weaker associations were observed at three other loci 
and, while they are not considered here to be significant, 
for completeness they were included in the meta-analysis. 
r2522051 (LOC441108) showed a recessive association 
with anti-MSP1 levels (beta = −0.06, P =  6.4 ×  10−4). 
rs156029 (P4HA2) showed heterozygous association 
with anti-AMA1 levels (beta  =  −0.05, P  =  9.7×10−4). 
rs542998 (RTN3) showed recessive association with 
anti-MSP1 levels (beta  =  0.06, P  =  8.8  ×  10−4). No 
associations were found for antibody levels to (NANP)4 
(Additional file  16). Including parasite density in the 
model did not appreciably change these findings (Addi-
tional file 17).
In order to look at the consistency of effect we have 
made forest plots of the betas. Figure  5 shows the beta 
values, 95  % confidence intervals and p-values for the 
effect of HbAS on the four anti-malarial antibodies at 
each site. The direction of effect is mostly consistent 
across sites for the three merozoite antibodies but no 
effect was seen at any site for anti-(NANP)4 antibodies, 
except in Mali (Pongonon). The results of meta-analysis 
for the 4 marginal genes (CD36 and LOC441108, P4HA2 
and RTN3) are shown in Additional file 18 as forest plots 
along with their p-values.
Association of HbAS and malaria infection
Given the association between sickle and anti-malar-
ial antibody levels (see above), a regression analyses 
was conducted between malaria infection (microscopy 
result and parasite density) and sickle cell trait. HbAS 
individuals were significantly protected from becoming 
Table 3 Results of  linear regression analysis investigating the effect of  age, gender and  malaria status as  determined 
by microscopyb on logged antibody levels to AMA1, MSP1, MSP2, NANP and IgE
Results shown as betas, which indicate the direction of effect of the clinical covariate on antibody levels. Beta < 0 indicate a decrease in antibody levels and beta > 0 
indicate an increase in antibody levels. 95 % confidence intervals that do not span 0 indicate an effect that is significant at p = 0.05.
NB: CI confidence interval; results significant at 0.05 level are highlighted in italics.
a Data not available for Tanzania (Moshi).
b  Also adjusted for village (>20), ethnicity (>20), sample month (>20) and study; results not shown but ANOVA p-values were <0.001 for all antibodies.
Factor Anti-AMA1 levels 
(n = 10,137)
Anti-MSP1 levels 
(n = 10,200)
Anti-MSP2 levels 
(n = 10,283)
Anti-NANP levels 
(n = 5,531)a
Total IgE levels 
(n = 4,961)a
Beta (95 % CI) p-value Beta (95 % CI) p-value Beta (95 % CI) p-value Beta (95 % CI) p-value Beta (95 % CI) p-value
Age (years)
 <1 0 0 0 0 0
 1–2 0.04 (−0.09 to 
0.17)
0.576 −0.10 (−0.22 to 
0.01)
0.083 0.16 (0.05 to 0.28) 0.006 0.30 (0.04 to 0.55) 0.023 0.09 (−0.17 to 
0.35)
0.508
 2–5 0.25 (0.15 to 0.35) <0.001 0.08 (−0.01 to 
0.17)
0.087 0.29 (0.20 to 0.38) <0.001 0.50 (0.30 to 0.71) <0.001 0.09 (−0.12 to 
0.30)
0.398
 5–15 0.57 (0.47 to 0.67) <0.001 0.37 (0.28 to 0.45) <0.001 0.61 (0.52 to 0.69) <0.001 0.87 (0.67 to 1.07) <0.001 0.19 (−0.01 to 
0.40)
0.066
 15–30 0.55 (0.46 to 0.65) <0.001 0.65 (0.57 to 0.74) <0.001 0.72 (0.63 to 0.81) <0.001 1.43 (1.23 to 1.63) <0.001 0.22 (0.02 to 0.43) 0.034
 >30 0.53 (0.43 to 0.63) <0.001 0.81 (0.72 to 0.90) <0.001 0.72 (0.63 to 0.81) <0.001 1.61 (1.40 to 1.81) <0.001 0.14 (−0.07 to 
0.35)
0.179
Gender
 Female 0 0 0 0 0
 Male −0.03 (−0.07 
to 0)
0.058 −0.08 (−0.11 to 
−0.05)
<0.001 −0.05 (−0.07 to 
−0.02)
0.002 −0.07 (−0.11 to 
−0.03)
0.004 0.12 (0.09 to 0.16) <0.001
Microscopy result
 Negative 0 0 0 0 0
 Positive 0.17 (0.13 to 0.22) <0.001 0.15 (0.11 to 0.19) <0.001 0.21 (0.18 to 0.25) <0.001 −0.03 (−0.08 to 
−0.02)
0.263 0.06 (0.01 to 0.11) 0.021
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microscopically positive for malaria infection (OR = 0.75, 
P  =  0.005; Table  2). A further analysis of parasitaemia 
levels at six sites providing information showed that 
overall there was no difference between HbAA and HbAS 
individuals (Additional file  8). Compared to infants 
(<1 year-olds) levels of parasitaemia increased in the 1–2 
and 2–5 years-old groups and then decreased into adult-
hood (Additional file 8).
Discussion
This dataset highlights considerable differences in 
malaria prevalence, antibody titres and study design 
between the sites that provided data. There are challenges 
associated with combining heterogeneous data; however, 
after quality control, a large dataset was compiled with 
13,299 individuals typed for 178 SNPs, measures for five 
antibody levels and a range of clinical covariates.
Of the ten sites in the study two found a 0 % prevalence 
(Sudan and Sri Lanka) at the time of sampling as meas-
ured by microscopic positivity and two had an ascertain-
ment design not allowing an analysis of effect of age on 
malaria prevalence (Mali-Pongonon and Kenya). Across 
the remaining studies, there was a significant increase 
in the odds of having microscopically positive malaria 
from the 1  year-old to 5–15  years-old age groups (OR 
3.49, P  <  0.001), after which prevalence declined into 
adulthood (OR 0.63, P =  0.01 30 vs 1  year-old groups). 
This is similar to that observed at individual site studies 
[28–31]. Many factors can influence the prevalence of 
malaria but the age effect is assumed to reflect acquired 
immunity to the parasite. Infants are protected against 
clinical infection [32–34], possibly due to the presence of 
foetal haemoglobin [35–37], maternal antibodies [35, 38] 
and lactoferrin in breastmilk [39]. The risk of becoming 
Fig. 4 Plot for 178 SNPs with logged anti‑malarial antibody levels. Values of –log10 p‑values plotted against chromosomal positions; only the lowest 
meta‑analysis p‑value for each SNP‑antibody association is plotted. The red dotted line indicates a Bonferroni threshold p‑value of 6 × 10−5. Each 
colour represents a different anti‑malarial antibody while the shape of the point represents the genetic model of best fit for the SNP‑antibody asso‑
ciation: (circle) for additive, (triangle) for dominant, and (square) for heterozygote and (plus) for recessive. Adjusted for age, gender, microscopy result, 
village (>20), ethnicity (>20), sample month (>20) and study.
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infected with malaria then increases as this protection 
wanes. During this and subsequent periods, exposure 
to malaria during childhood induces immunity [40–42], 
with an increasing repertoire of epitopes recognized [43], 
such that adults are at lower risk of acquiring or carrying 
malaria parasites than children and adolescents.
Microscopic malaria prevalence at a site did not 
always predict the magnitude of the anti-malarial 
antibody response. In Sri Lanka falciparum and vivax 
prevalence has been decreasing to almost zero by the 
time of plasma collection for this study [17] yet anti-
falciparum antibody titres were similar to those in 
the Tanga SP2 study where the prevalence was 37  %. 
It is believed that once immunity has been acquired 
then exposure to malaria parasites, even at sub-
microscopic parasitaemia [44, 45], may be sufficient 
Fig. 5 Forest plot of the HbS (rs334) association with antibodies to AMA1, MSP1, MSP2 and NANP. Points correspond to beta values obtained from 
meta‑analysis of results obtained from linear regression models of SNP with logged antibody levels, adjusted for relevant clinical covariates. Lines 
represent 95 % confidence intervals. Each colour represents a different antibody while the shape of the point represents the antibody type: (circle) 
for anti‑merozoite and (triangle) for anti‑ sporozoite. Summary of meta‑analysis betas obtained from combined data are represented as (square). 
Summary P‑values: ama1 = 2.9 × 10−07; msp1 = 1.2 × 10−06; msp2 = 6.5 × 10−07; nanp; = 0.2.
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to boost antibody levels through long-term memory 
[46–48], therefore, helping to maintain antibody titres 
in regions (Sri Lanka and Sudan) of low endemicity in 
this study.
As expected, antibody titres to asexual blood stage 
antigens were most highly correlated with each other 
(r2 > 0.3), and showed less correlation with anti-(NANP)4 
antibodies (r2 between 0.2 and 0.3) which are reflective 
of exposure to pre-erythrocytic parasites (sporozoites 
and liver stages). All anti-malarial antibodies showed 
similar distributions and peak titres from 1:100 to 
1:1,000. Total IgE levels were not correlated with any of 
the other antibody levels. Although there was a margin-
ally significant increase in total IgE levels with malaria 
infection, it was not possible to corroborate whether this 
was due to polyclonal induction of IgE antibodies dur-
ing malaria infection [49–51] or changes in specific anti-
malarial IgE.
A regression model was used to investigate the associa-
tion of clinical variables with antibody titres. As reported 
previously [52–54] increasing age was found to be signifi-
cantly associated with increased levels of antibodies to 
AMA1, MSP1, MSP2, and (NANP)4. A plateau effect was 
also seen with anti-AMA1, anti-MSP1 and anti-MSP2 in 
the older age groups similar to Calissano et al. [55].
As reported previously, being male was associated 
with decreased antibody levels to malarial antigens. Two 
contributing factors reported to explain this gender dif-
ference are the differential transcription and translation 
of IFN-γ between males and females [56] or an immu-
nosuppressive effect of testosterone in males [57]. Con-
versely, being male was significantly associated with 
an increase in total IgE levels, which is consistent with 
other studies [58–60]. One other likely explanation 
is due to the different habits of males and females and 
their exposure to helminth and other parasitic infections 
[61–63].
As expected [49, 53], microscopically positive infection 
was significantly associated with increased antibody lev-
els to the merozoite antigens AMA1, MSP1 and MSP2. 
Furthermore, the presence of these asexual stages was 
not associated with antibody titres to the pre-erythro-
cytic antigen (NANP)4 [64].
A regression model was used to investigate SNP 
associations with antibody levels that included several 
covariates for parameters that were identified as influ-
encing antibody levels. Of all the SNPs and antibodies 
the most significant effect was seen for rs334 (HbS) 
with reduced antibody titres to merozoite antigens. 
Previous research has been inconsistent regarding the 
relationship between sickle cell trait and IgG responses 
to malaria: some studies have reported higher antibody 
levels in HbAS compared to HbAA individuals [65], 
whilst others have reported lower antibody levels in 
HbAS individuals [30], or even no difference between 
the two [54]. Miura et al. [30] found that HbAS children 
in Mali had significantly lower IgG levels to EBA175 
and MSP2 compared to their HbAA counterparts and 
also tended to have lower IgG levels to AMA1 and 
MSP1, although these latter findings were not statis-
tically significant. Several studies measured tetanus 
toxoid-specific IgG titres in HbAA and HbAS children 
and found no differences [30, 65], which Verra et  al. 
[65] used to infer that HbAS children had lower IgG 
titres specifically to merozoite antigens. This specificity 
is confirmed in this study by finding significant differ-
ences in anti-AMA1, anti-MSP1 and anti-MSP2 levels 
but not in anti-(NANP)4 or total IgE levels. Verra et al. 
[65] concluded that the lowered IgG levels in HbAS 
children found in their study suggest that the malaria-
protective effects of HbAS are not due to malaria-spe-
cific IgG responses.
The most likely mechanism for lowered antibody lev-
els in HbAS individuals is by reducing the net expo-
sure of the immune system to parasites; for example, 
by reducing invasion and development of parasites in 
HbAS erythrocytes [30, 54], enhancing phagocytosis 
of infected HbAS erythrocytes [30, 54, 65, 66], or by 
accelerating the removal of parasitized erythrocytes by 
the spleen through sickling [66]. These are all consist-
ent with the observation (n  =  9,227 individuals) that 
HbAS significantly reduced the odds of being micro-
scopically positive compared to HbAA. Taken together 
with a significant reduction in anti-merozoite antibod-
ies and no change in antibodies to pre-erythrocytic 
stages, the data suggest that HbAS affects asexual 
blood-stages only. One possible explanation would 
be for HbAS to exert its effect early after the release 
of merozoites from the liver by blocking or delaying 
growth in infected erythrocytes. If this were the case, 
then the time to establish a patent infection would be 
increased/extended thereby reducing exposure to the 
immune system. However, once a blood-stage infection 
is established the data (n =  2,272) suggest that HbAS 
erythrocytes are no longer able to attenuate parasite 
growth.
Indeed across 21 published studies, the majority 
having less than 1,000 individuals, there is no con-
sensus on the effect of HbAS on parasite density or 
prevalence, although the weight of evidence is prob-
ably for no effect (review and meta-analysis [67]). It is 
still unknown whether parasites infecting HbAS and 
HbAA erythrocytes differ in virulence, but it is clear 
that in the absence of controlling parasitaemia, HbAS 
is highly protective against severe malaria phenotypes 
[21, 67].
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There are several features of this study that increase 
the reliability of the associations found between 
HbAS and merozoite antibodies. Firstly, a large 
dataset was generated with over 13,000 individuals, 
12,380 of whom were HbAA and 868 HbAS. Sec-
ondly, a similar effect size was found for HbS in asso-
ciation with anti-AMA1, anti-MSP1 and anti-MSP2 
levels, using the heterozygote model. Thirdly, the 
p-values for each HbAS-antibody association were 
similar and highly significant even after adjusting for 
multiple testing. Finally, not including an interac-
tion term between SNP and study in the model meant 
that all significant outcomes represented effects that 
were consistent across sites, as demonstrated in the 
Forest plots for HbAS with the merozoite antibod-
ies. The only exceptions were the Manteourou study 
in Mali and the Sri Lanka study, which had oppo-
site directions of effect to the other sites for anti-
AMA1. Neither of these associations were significant 
and were likely due to relatively small sample sizes 
(Mali  =  643, Sri Lanka  =  497) combined with low 
derived allele frequencies for HbAS (Mali = 1.5 %; Sri 
Lanka = 0.4 %).
One SNP was found to be marginally associated with 
antibody levels to merozoite antigens. The SNP in CD36 
(rs3211938) on chromosome 7 was associated with a 
reduction in anti-MSP2 levels using the recessive genetic 
model, which is consistent with the reduced anti-MSP1 
levels observed in individuals recessive homozygous for 
this SNP in another area of Tanzania [68]. None of the 
other loci tested here showed evidence of association 
with antibodies in this multi-centre analysis with a sig-
nificance of P < 10−4.
Conclusion
A major strength of this study was its large sample 
size (n =  13,299), which enabled the detection of an 
effect of SNPs on antibody levels even at a signifi-
cance level adjusted for multiple testing. The sample 
size also allowed adjustment for a multitude of poten-
tial confounding factors, and having participants from 
ten sites in seven different countries sampled using 
standardized methodologies allowed an analysis for 
consistency of SNP effect across sites. This study finds 
an association of HbS (rs334) carriage with lowered 
antibody levels to merozoite antigens AMA1, MSP1 
and MSP2, that is highly significant and consistent 
across study sites. This study demonstrates the feasi-
bility of combining data from heterogeneous sources 
and the findings support the notion that genetic fac-
tors can determine an individual’s immune response 
to malaria.
Additional files
 Additional file 1: Additional Table ST1 Details of Principal Investigators 
and Ethics Review Committees for each site. Details of Principal Investiga‑
tors and Ethics Review Committees for each site.
Additional file 2: Additional Table ST2: Details of covariates adjusted for 
in linear regression analysis of non‑genetic factors with logged antibody 
levels, their relevance to the study and their previous association(s) with 
malaria or anti‑malarial antibodies. Information on the covariates used in 
this study as con‑variates in the various analyses.
Additional file 3: Additional File LFST1A: Details of gene regions 
selected for genotyping and the SNP assay design details. This file con‑
tains a list of the genes from which SNPs were selected and typed for this 
study. Information is provided on the gene and its genomic location with 
respect to the Human Reference genome build GRCh37. Also provided is 
a table containing the assay design details for each SNP used in this study 
for the Agena Biosciences iPLEX genotyping platform. SNPs are grouped 
into multiplexes as assigned by the assay design software.
Additional file 4: MalariaGEN Supplementary Sample Handling 
Procedures. This file includes more detail on sample handling proce‑
dures including extracting DNA, genotyping methodology, ELISA proto‑
cols with ELISA data processing.
Additional file 5: Additional Figure SF1: Histograms of logged antibody 
levels before further manipulations were made. Histograms of the logged 
antibody titres across all samples for each antibody measured in this 
study.
Additional file 6: Additional Figure SF2: Histograms of residuals from 
antibody linear regression models with non‑genetic factors. Histograms 
of the residuals from the antibody linear regression model analysis with 
non‑genetic factors.
Additional file 7: Additional Table ST3A‑D: Details of the linear regres‑
sion models used in this study. Model formulae for the various linear 
regression analyses showing how the different co‑variates were used.
Additional file 8: Additional Table ST4: Results of linear regression analy‑
sis investigating the effect of age, gender and HbS genotype on parasite 
density in malaria‑positive individuals using combined site data. Results 
of linear regression analysis investigating the effect of age, gender and 
HbS genotype on parasite density in malaria‑positive individuals using 
combined data. This is an extension to that shown in the main text and is 
a reduced dataset as not all sites provided parasitaemia data.
Additional file 9: Additional figure SF3: Heatmap matrix plot of the 
correlations between residuals from the antibody linear regression models 
with non‑genetic factors at each site. Matrix plot of the pairwise correla‑
tions as r2 between antibody titres using data from all sites.
Additional file 10: Additional figure SF4: Scatter plot of the correlations 
between residuals from the antibody linear regression models with non‑
genetic factors at each site and age‑group. This plot shows the pairwise 
correlations (as r2) for each malaria–malaria antibody pair as a function 
of each study site. The sites are ordered according to malaria microscop‑
ically‑positive‑prevalence recorded at sample collection (low to high). 
Several panels are shown according to age‑group.
Additional file 11: Additional table ST5: Linear regression analysis of the 
correlations between residuals from the malaria antibody pairs. This data 
shows the results of the analysis of the correlations between antibodies.
Additional file 12: Additional Table ST6: Results of linear regression 
analysis investigating the effect of age, gender and parasite density on 
logged antibody levels to AMA1, MSP1, MSP2, NANP and IgE. Results 
of linear regression analysis investigating the effect of age, gender and 
parasite density using combined data for each antibody measured in this 
study. This is an extension to that shown in the main text and is a reduced 
dataset as not all sites provided parasitaemia data.
Additional file 13: Additional Table ST7A–E: Results of site‑specific 
linear regression analysis investigating the effect of age, gender and 
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malaria status as determined by microscopy on antibody levels to the 
different antibodies measured in the study. This data shows the site‑
specific analyses of the various epidemiological parameters and antibody 
measurements.
Additional file 14: Additional Table ST8: Results of linear regression anal‑
ysis investigating the effect of age, gender, malaria status as determined 
by microscopy and bednet use* on logged antibody levels to AMA1, 
MSP1, MSP2, NANP and IgE. This table shows the results of the analysis of 
antibody levels with bednet use. Results shown as betas indicating the 
direction of effect of the clinical covariates on antibody levels.
Additional file 15: Additional Table ST9: Details of 196 genotyped SNPs 
and their derived allele frequencies at each site. This table shows allele fre‑
quencies for each SNP analysed in this study according to each study site.
Additional file 16: Additional Table ST10: Meta‑analysis p‑values 
obtained for 178 SNPs passing QC criteria detailed in materials and meth‑
ods. Details of the analyses for each SNP and antibody across all sites for 
different genetic inheritance models.
Additional file 17: Additional Figure SF5: Plot for 178 SNPs with logged 
anti‑malarial antibody levels. Plot for the P‑values of the analyses of 178 
SNPs with logged anti‑malarial antibody levels Adjusted for age, gender, 
parasite density, village (>20), ethnicity (>20), sample month (>20) and 
study. This is an extension to that shown in the main text and is a reduced 
dataset as not all sites provided parasitaemia data.
Additional file 18: Additional Figure SF6: Forest plot of the association 
of A: CD36 (rs3211938), B: LOC441108 (rs2522051), C: RTN3 (rs542998) and 
D: P4HA2 (rs156029) with antibody levels to AMA1, MSP1, MSP2 and NANP. 
Forest plots of the betas obtained from meta‑analysis of results obtained 
from linear regression models of SNP with logged antibody levels, 
adjusted for relevant clinical covariates.
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